By: IPP Bureau
Last updated : October 23, 2025 5:18 pm
Takeda will make an upfront payment of $1.2 billion, which includes a $100 million equity investment in Innovent
Takeda Pharmaceutical has entered a global strategic partnership with Innovent Biologics to advance the development of next-generation oncology medicines for solid tumors, in a deal potentially worth up to $11.4 billion. The collaboration focuses on Innovent's cutting-edge immuno-oncology (IO) and antibody-drug conjugate (ADC) assets.
Takeda will make an upfront payment of $1.2 billion, which includes a $100 million equity investment in Innovent. Innovent is eligible for up to $10.2 billion in additional milestone payments, plus tiered royalties on potential sales.
Through this collaboration, Takeda gains worldwide rights outside of Greater China to two late-stage oncology candidates — IBI363 and IBI343 — and an exclusive option to license global rights to an early-stage program, IBI3001.
Under the agreement, Takeda will lead global co-development and U.S. co-commercialization of IBI363, a late-stage bispecific antibody fusion protein being evaluated in non-small cell lung cancer (NSCLC) and colorectal cancer, with potential across additional solid tumor types.
Takeda will have exclusive commercialization rights for IBI363 outside the U.S. and Greater China and plans to establish manufacturing for this program in the U.S. IBI343, a late-stage antibody-drug conjugate (ADC) targeting Claudin 18.2, is being studied in gastric and pancreatic cancers. Takeda will hold exclusive development, manufacturing, and commercialization rights for IBI343 worldwide outside of Greater China.
“IBI363 and IBI343 represent the next generation of cancer therapeutics with the potential to address critical treatment gaps for patients with solid tumors,” said Teresa Bitetti, President, Global Oncology Business Unit, Takeda. “We are excited to collaborate with Innovent to accelerate their development and deliver these promising medicines to patients globally. These programs will further strengthen our oncology portfolio and support Takeda’s long-term growth beyond 2030.”
“This partnership significantly enhances our late-stage oncology pipeline and aligns with our strategy to deliver transformative medicines to patients with difficult-to-treat cancers,” said Andy Plump, President, Research and Development, Takeda. “With our global R&D and commercialization expertise, we are well positioned to advance these innovative programs and realize their full potential.”
IBI3001, a bispecific ADC targeting EGFR and B7H3, is currently being evaluated in an ongoing Phase 1 trial in patients with advanced solid tumors. Innovent will continue development of IBI3001 until Takeda decides whether to exercise its option to license global rights outside Greater China.
“We are proud to partner with Takeda, a global leader in oncology, to advance our innovative immuno-oncology and ADC pipeline,” said Dr. Hui Zhou, Chief R&D Officer for Oncology Pipeline at Innovent Biologics. “Together, we aim to accelerate the development of these promising therapies and bring new hope to patients with cancers that currently have limited treatment options.”